scholarly article | Q13442814 |
P50 | author | Jon Stoessl | Q20006927 |
Kazuko Hasegawa | Q64858707 | ||
Vesna Sossi | Q67175776 | ||
M Schulzer | Q67209622 | ||
E Mak | Q67210951 | ||
Daryl J Wile | Q67212681 | ||
Audrey J Strongosky | Q114336738 | ||
Katherine Dinelle | Q117251250 | ||
Nasim Vafai | Q117251251 | ||
Jessamyn McKenzie | Q117251252 | ||
Nicole Neilson | Q117251253 | ||
Cyrus P Zabetian | Q30362040 | ||
Pankaj A Agarwal | Q42838307 | ||
Elham Shahinfard | Q57066883 | ||
Ryan J Uitti | Q64754354 | ||
Zbigniew K Wszolek | Q64754704 | ||
P2093 | author name string | Jing Zhang | |
Mark Guttman | |||
Yu-Shin Ding | |||
Jan Aasly | |||
Mike Adam | |||
P2860 | cites work | ??? | Q64786077 |
Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 | ||
Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations | Q28236042 | ||
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice | Q29620597 | ||
Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study | Q33668068 | ||
Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease | Q34267681 | ||
Brain serotonin transporter binding in non-depressed patients with Parkinson's disease | Q34619565 | ||
Spared caudal brainstem SERT binding in early Parkinson's disease | Q34724279 | ||
Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. | Q34801837 | ||
Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers | Q35119612 | ||
Olfactory dysfunction in LRRK2 G2019S mutation carriers | Q35119617 | ||
Distribution volume ratios without blood sampling from graphical analysis of PET data | Q36817029 | ||
Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes | Q37243261 | ||
Prediagnostic presentations of Parkinson's disease in primary care: a case-control study | Q39092409 | ||
Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers | Q39477657 | ||
Dopamine turnover increases in asymptomatic LRRK2 mutations carriers | Q42861721 | ||
Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. | Q42872557 | ||
Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study | Q42994792 | ||
Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study | Q43290056 | ||
Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease | Q45271401 | ||
Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease | Q45346135 | ||
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation | Q46635617 | ||
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease | Q46935041 | ||
DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease. | Q47907932 | ||
Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter | Q48121057 | ||
Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study | Q48123682 | ||
Serotonergic mediated body mass index changes in Parkinson's disease. | Q53222060 | ||
Olfactory heterogeneity in LRRK2 related Parkinsonism. | Q54651567 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | parkinsonian syndrome | Q1531991 |
P304 | page(s) | 351-359 | |
P577 | publication date | 2017-03-20 | |
P1433 | published in | Lancet Neurology | Q15755067 |
P1476 | title | Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies | |
P478 | volume | 16 |
Q64866418 | Q64866418 |
Q58598324 | A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein |
Q58730704 | Altered dopamine release and monoamine transporters in Vps35 p.D620N knock-in mice |
Q89776335 | Clinical and Dopamine Transporter Imaging Characteristics of Leucine- Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study |
Q95840882 | Clinical and Imaging Markers of Prodromal Parkinson's Disease |
Q91069104 | Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study |
Q48172009 | Cognitive and behavioral disorders in Parkinson's disease: an update. I: cognitive impairments |
Q53692679 | Disease progression in LRRK2 parkinsonism. |
Q57158118 | Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder |
Q42268862 | Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice |
Q55287139 | Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET. |
Q89521076 | Is serotonin pathology a good biomarker in vivo for early Parkinson's disease? |
Q40964593 | Neurochemical Systems of the Retina Involved in the Control of Movement. |
Q92959125 | Serotonergic pathology and Braak's staging hypothesis in Parkinson's disease |
Q92959120 | Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study |
Q64759313 | Structural Imaging in Parkinson's Disease: New Developments |
Q49886566 | The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. |
Search more.